China's NMPA approved Medytox's Neuramis Deep Lidocaine hyaluronic acid filler, reported June 25, where it will be sold under the brand name Filux. For a US or Gulf practice this is not a product you will stock, but it is a read on where Korean filler supply is heading. Distribution runs through Hainan Steou Investment Co. under a five-year exclusive agreement signed at the end of 2024, and Hainan Steou plans to work with Sinopharm, one of China's largest pharma groups, on marketing and distribution reach.

The wider pattern is the part to file away. Medytox plans to add to its filler lineup in Q4 2026, and the China entry is one more step in Korean manufacturers pushing volume into the largest aesthetics market in Asia. More Korean HA capacity and more competition tends to filter back into global pricing and into the menu of products distributors eventually pitch you. Worth noting if you track filler sourcing or cost trends.

Source: Seoul Economic Daily — https://en.sedaily.com/finance/2026/06/25/medytox-wins-china-approval-for-neuramis-ha-filler